Stocks and Investing
Stocks and Investing
Wed, October 23, 2019
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Andrew Fein Reiterated (BIIB) at Strong Buy with Increased Target to $335 on, Oct 23rd, 2019
Andrew Fein of HC Wainwright & Co., Reiterated "Biogen Inc." (BIIB) at Strong Buy with Increased Target from $300 to $335 on, Oct 23rd, 2019.
Andrew has made no other calls on BIIB in the last 4 months.
There is 1 other peer that has a rating on BIIB. Out of the 1 peers that are also analyzing BIIB, all agrees with Andrew's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Christopher Raymond of "Piper Sandler" Downgraded from Buy to Hold and Decreased Target to $250 on, Friday, June 28th, 2019
Contributing Sources